Radicular cyst in primary dentition showing angiolymphoid hyperplasia with eosinophilia (ALHE)-like features: An immunohistochemical study

The microscopical diagnosis of radicular cyst (RC) is straightforward; nonetheless, in some cases with unusual histopathological features, strict clinicopathological correlation is necessary to achieve the correct diagnosis. We report a case of a 5-year-old girl was referred presenting extensive carious lesion in the tooth #55, associated with vestibular sinus tract. Medical history revealed allergic asthma diagnosis. After clinical and imagi-nological exams, the deciduous tooth was extracted. Microscopically, the soft tissue lesion attached to the root showed typical RC features; however, in the cystic capsule, lymphoid follicles and vascular networks (lined by epithelioid endothelial cells) surrounded by nu-merous eosinophils, were observed. Immunohistochemistry, through CD3, CD20, CD34 and alpha-smooth muscle actin antibodies, highlighted these findings. Moreover, CD1a and CD207 were negative. To the best of our knowledge, this is the first report of RC showing angiolymphoid hyperplasia with eosinophilia (ALHE)-like features. (AU)

Suspensión de antirresortivos en osteonecrosis asociada a medicamentos: revisión de la literatura / Suspension of antiresorptive drugs in medication-related osteonecrosis of the jaws: a review of the literature

La suspensión de antirresortivos en el contexto de cuadros de osteonecrosis asociada a medicamentos (ONAM) es controversial. Aunque la evidencia de ca-lidad al respecto es insuficiente, múltiples socieda-des profesionales y grupos de trabajo han sugerido emplear este recurso. Recientemente la Sociedad Americana de Cirujanos Orales y Maxilofaciales ha puesto en duda sus beneficios. En el presente estudio abordamos esta temática en dos situaciones clínicas diferentes. Por un lado, analizamos la suspensión de los antirresortivos en pacientes asintomáticos an-tes de llevar a cabo procedimientos invasivos en los maxilares para disminuir el riesgo de desarrollo de ONAM. Por otro lado, evaluamos la suspensión de los antirresortivos en pacientes con ONAM establecida para mejorar el pronóstico de la enfermedad (AU)

The suspension of antiresorptive drugs in the context of medication-related osteonecrosis of the jaws (MRONJ) is controversial. Despite the lack of quality evidence, several professional associations and working groups have made suggestions in using this resource. Recently the American Association of Oral and Maxillofacial Surgeons has questioned its benefits. In the present study we address this issue in two different clinical situations. On the one hand, we analyzed the suspension of antiresorptive agents in asymptomatic patients before carrying out invasive procedures in the jaws to reduce the risk of developing MRONJ. On the other hand, we evaluated the suspension of antiresorptive drugs in patients actually presenting MRONJ to improve the prognosis of the disease (AU)

Denosumabe e osteonecrose dos maxilares: o que o cirugião-dentista precisa saber? / Denosumab and osteonecrosis of the jaws: what does the dental surgeon need to know? / Denosumab y osteonecrosis de mandíbulas: ¿qué necesita saber el cirujano dental?

Introdução:O Denosumabeé um fármaco antirreabsortivo indicado para o tratamento de osteoporose e doenças ósseas metastáticas. O seu uso está associado ao desenvolvimento de reações adversas em diferentes órgãos, como a osteonecrose dos maxilares, que é o evento adverso de interesseodontológico. Objetivo:Realizar um levantamento bibliográfico sobre o mecanismo de ação do Denosumabe no tecido ósseo e destacar a importância do cirurgião-dentista na prevenção, no diagnóstico e tratamento da osteonecrose nos maxilares.Metodologia:Trata-se de uma revisão integrativa elaboradaem duas etapas: inicialmente realizou-se uma busca de artigos publicados entre os anos 2010a 2022, sobre a osteonecrose em pacientes que fazem uso do Denosumabe nas plataformas de dados Pubmed, ScieloeBiblioteca Virtual em Saúde. Posteriormente, foi feita uma seleção de partes relevantes para a pesquisa, uma leitura analítica e a organização das informações coletadas pertinentes a cada tópico da pesquisa.Resultados:ODenosumabe inibea ligação da citocina RANKL ao seu receptor RANK, tal mecanismo de ação reduz o processo de reabsorção óssea execessiva. As osteonecroses podem apresentar-se em diferentes níveis de estadiamento e caracterizam-se como área de exposição óssea necrótica na região maxilofacial, permanecendo por mais de oito semanas e sem histórico de radioterapia ou doença metastática evidentes nos maxilares. Alguns fatores predispõem o desenvolvimento das osteonecroses, entre eles: procedimentos odontológicos cirúrgicos. Ainda não existe um protocolo de tratamento definitivo, entretanto, modalidades terapêuticas coadjuvantes são administradas de acordo com a condição clínicado paciente.Conclusões:O exame clínico deve ser minucioso, atentando-se a qualquer alteração na cavidade bucal, às doenças preexistentes e às medicações utilizadas pelo paciente. Em todos os casos deve-se, realizar orientações de higiene oral e adequação do meio bucal previamente ao tratamento oncológico e ao uso de drogas antirreabsortivas (AU).

Introduction:Denosumab is an antiresorptive drug indicated for the treatment of osteoporosis and metastatic bone diseases. Its use is associated with the development of adverse reactions in different organs, such as osteonecrosis of the jaws, which is an adverse event ofdentalinterest.Objective:Conducta bibliographic survey on the mechanism of action of Denosumab in bone tissue and to highlight the importance of the dentist in the prevention, diagnosis and treatment of osteonecrosis in the jaws. Methodology: This is an integrative review carried out in two stages: initially, a search was carried out for articles published between the years 2010to 2022, on osteonecrosis in patients using Denosumab in the data platforms Pubmed, Scieloand Virtual Health Library(BVS). Subsequently, a selection of relevant parts for the research was made, an analytical reading and the organization of the collected information pertinent to each research theme was carried out.Results:TheDenosumab inhibitsthe binding of the RANKL cytokine to its RANK receptor, this mechanism of action reduces the process of excessive bone resorption. Osteonecrosis can present at different staging levels and are characterized as an area of necrotic bone exposure in the maxillofacial region, lasting for more than eight weeks and without a history of radiotherapy or evident metastatic disease in the jaws. Some factors predispose the development of osteonecrosis, including: surgical dental procedures. There is still no definitive treatment protocol, however, supporting therapeutic modalities are administered according to the patient's clinical condition.Conclusions:The clinical examination must be thorough, paying attention to any changes in the oral cavity, pre existing diseases and medications used by the patient. In all cases, guidelines on oral hygiene and adequacy of the oral environment should be carried out prior to oncological treatment and the use of antiresorptive drugs (AU).

Introducción: Denosumab es un fármaco antirresortivo indicado para el tratamiento de la osteoporosis y enfermedades óseas metastásicas. Su usoestá asociado al desarrollo de reacciones adversas en diferentes órganos, comola osteonecrosis de los maxilares, que es un evento adverso de interés odontológico. Objetivo: Realizar un levantamiento bibliográfico sobre el mecanismo de acción de Denosumab en el tejido óseo y resaltar la importancia del odontólogo en la prevención, diagnóstico y tratamiento de la osteonecrosis en los maxilares. Metodología: Esta es una revisión integradora realizada en dos etapas: inicialmente se realizó una búsqueda de artículos publicados entre los años 2010 a 2022, sobre osteonecrosis en pacientes usuarios de Denosumab en las plataformas Pubmed, ScieloyBiblioteca Virtual en Salud(BVS).Posteriormente, se realizó una selección de partes relevantes para la investigación, se realizó una lectura analítica y la organización de la información recolectada relevante para cada tema de investigación. Resultados:Denosumab inhibela unión de la citoquina RANKL a su receptor RANK, este mecanismo de acción reduce el proceso de reabsorción ósea excesiva. La osteonecrosis puede presentarse en diferentes nivelesde estadificación y se caracterizan por un área de exposición ósea necrótica en la región maxilofacial, con una duración mayor a ocho semanas y sin antecedentes de radioterapia o enfermedad metastásica evidente en los maxilares. Algunos factores predisponen al desarrollo de osteonecrosis, entre ellos: procedimientos quirúrgicos dentales. Aún noexiste un protocolo de tratamiento definitivo, sin embargo, se administran modalidades terapéuticas de apoyo de acuerdo a la condición clínica del paciente.Conclusiones: El examen clínico debe ser minucioso, prestando atención a cualquier cambio en la cavidad bucal, enfermedades preexistentes y medicamentos utilizados por el paciente. En todos los casos se deben realizar pautas de higiene bucal y adecuación del medio bucal previo al tratamiento oncológico y al uso de fármacos antirresortivos (AU).

Osteonecrosis mandibular: hallazgos clínicos e imagenológicos en un paciente tratado con denosumab / Mandibular osteonecrosis: clinical and imaging findings in a patient treated with denosumab

Introducción: La administración de bifosfonatos y medicamentos antiangiogénicos en pacientes con cáncer es un esquema terapéutico usual en oncología. Existen reportes de osteonecrosis de los maxilares en pacientes sometidos a este esquema de tratamiento, luego de realizar un procedimiento dental invasivo. Objetivo: A partir de las características clínicas e imagenológicas de la patología, ilustrar al odontólogo sobre los medicamentos para el tratamiento del cáncer, susceptibles de generar osteonecrosis de los maxilares. Presentación de caso: Paciente masculino de 89 años, con cáncer de próstata tratado con denosumab, que desarrolló osteonecrosis del maxilar inferior posterior a una extracción dental. Es de vital importancia que el odontólogo identifique los medicamentos, factores de riesgo y las medidas para minimizar el riesgo de osteonecrosis de los maxilares en pacientes susceptibles(AU)

Introduction: The administration of bisphosphonates and antiangiogenic drugs in cancer patients is a usual therapeutic scheme in oncology. There are reports of osteonecrosis of the jaws in patients undergoing this treatment scheme, after performing an invasive dental procedure. Objective: Show the dentist from the clinical and imaging characteristics of the pathology on the drugs for the treatment of cancer sensitivity to generate osteonecrosis of the jaws. Case presentation: An 89-year-old male patient with prostate cancer treated with denosumab developed osteonecrosis of the lower jaw after tooth extraction. It is vitally important that the dentist identifies medications, risk factors and measures to minimize the risk of osteonecrosis of the jaws in sensitivy patients(AU)

Ameloblastoma Differential Radiographic Findings in Children and Adolescents / Hallazgos Radiográficos Diferenciales de Ameloblastoma en Niños y Adolescentes

ABSTRACT: The aim of this research was to investigate the radiographic, clinical, and histological features of cases of ameloblastoma from a period of 17 years in a Brazilian center and to explore potential differences in children and adolescen ts in relation to adults. Seventy-five patients diagnosed with ameloblastoma from 2001 to 2018 were included. Data from each patient including gender, age, histologic type, location, and radiographic characteristics were reviewed and analyzed retrospectively. The association between the clinical, radiographic, and histologic findings was investigated. No differences regarding the histological pattern of the lesions were observed between groups. Children and adolescents presented well- defined lesions associated with an unerupted tooth compared to adults (p<0.05). The presence of an unerupted tooth was associated with cortical erosion and expansion and MC displacement (p<0.05). Despite similar histologic characteristics, differential radiographic appearance was observed between young patients and adults.

RESUMEN: El objetivo de este trabajo fue investigar las características radiográficas, clínicas e histológicas de casos de ameloblastoma en un período de 17 años, en un centro brasileño y explorar las posibles diferencias en niños y adolescentes en relación con los adultos. Se incluyeron 75 pacientes diagnosticados con ameloblastoma desde 2001 hasta 2018. Los datos de cada paciente, incluyendo el sexo, la edad, el tipo histológico, la ubicación y las características radiográficas, se revisaron y analizaron retrospectivamente. Se investigó la asociación entre los hallazgos clínicos, radiográficos e histológicos. No se observaron diferencias en cuanto al patrón histológico de las lesiones entre los grupos. Los niños y adolescentes presentaron lesiones bien definidas asociadas a un diente no erupcionado en comparación con los adultos (p<0,05). La presencia de un diente no erupcionado se asoció con erosión y expansión cortical y desplazamiento de MC (p<0,05). A pesar de las características histológicas similares, se observó una apariencia radiográfica diferente entre pacientes jóvenes y adultos.

Osteonecrosis de los Maxilares, Puesta al Día / Medication Related Osteonecrosis of the Jaw, Update

RESUMEN: La osteonecrosis también conocida como una necrosis avascular del hueso, es una condición degenerativa producida por la pérdida en la irrigación sanguínea, debido a la toxicidad directa en los tejidos óseos provocadas por quimioterapia, radioterapia, daño térmico, fumar y en la última década con la aparición de medicamentos como los bifosfonatos (BF), denosumab y medicamentos antigiogénicos, con los cuales hemos ido conociendo más sobre esta patología. La principal hipótesis de la fisiopatología de esta enfermedad es la inhibición de la angiogénesis, pero también se considera como hipótesis la toxicidad de los tejidos blandos o la disfunción adquirida de la inmunidad. En el año 2003 fue relatada por primera vez la relación entre BF y osteonecrosis maxilar (ONM). Ese mismo año fue descrito que pacientes con mieloma múltiple que recibían pamidronato podrían desarrollar necrosis avascular de los maxilares. Otras publicaciones informaban sobre pacientes que requerían tratamiento para necrosis ósea intra-oral de ocurrencia espontánea después de extracciones dentales o trauma oral. La primera denominación a esta patología fue (BRONJ) por sus siglas en inglés, se refería a ONM relacionada a BF. En 2014 la Asociación Americana de Cirujanos Orales y Maxilofaciales (AAOMS) publicó una nueva definición (position paper) renombrándolo como MRONJ (osteonecrosis de los maxilares relacionada a medicamentos) ONMRM. El rol en la identificación de pacientes con riesgo de ONMRM es fundamental. Los estudios han demostrado que el riesgo de desarrollar la afección se puede reducir sustancialmente si los pacientes son evaluados por un profesional dental y se toman medidas preventivas. La presente revisión narrativa realiza un recorrido desde la historia, los medicamentos involucrados, y diferentes estrategias de tratamientos propuestos, haciendo hincapié en la conducta que debemos seguir los cirujanos dentistas para enfrentar estos casos de forma temprana y prevenir su evolución.

ABSTRACT: Osteonecrosis is also known as avascular necrosis of the bone, it is a degenerative condition produced by the loss of blood flow, due to direct toxicity in the bone tissues caused by chemotherapy, radiotherapy, thermal damage, smoking and in the last decade with the arrival of drugs such as bisphosphonates (BP), denosumab and antigiogenic drugs we have been learning more about this pathology. The main hypothesis of the pathophysiology of this disease is the inhibition of angiogenesis, but soft tissue toxicity or acquired immunity dysfunction are also considered as hypotheses. In 2003, the relationship between BP and osteonecrosis of the jaws (ONJ) was reported for the first time. In the same year it was described that multiple myeloma patients receiving pamidronate could develop avascular necrosis of the jaws. Other publications reported about patients requiring treatment for spontaneously intra-oral bone necrosis after dental extractions or oral trauma. The first name for this pathology was (BRONJ) for its English acronym, it referred to ONJ related to BF. In 2014 the American Association of Oral and Maxillofacial Surgeons (AAOMS) published a new definition (position paper) renaming it MRONJ (drug-related osteonecrosis of the jaws) ONMRM. The role of identifying patients at risk of ONMRM is fundamental. Studies have shown that the risk of developing the condition can be substantially reduced if patients are evaluated by a dental professional and preventive measures are taken Exposure of bone or fistula that can be probed down to the bone in the maxillofacial region that persists for more than 8 weeks, with these conditions it is considered that there is a diagnosis of ONMRM This narrative review takes a journey from history, the drugs involved, and different proposed treatment strategies, emphasizing the behavior that dental surgeons must follow to face these cases early and prevent their evolution.

Medication-Related Osteonecrosis of the Jaw Associated with Pazopanib Monotherapy / Osteonecrosis de la Mandíbula Relacionada con Medicamentos Asociada con la Monoterapia con Pazobanib

ABSTRACT: Pazopanib, an antiangiogenic agent, has shown promising results in controlling tumor growth and metastasis in patients with renal cell carcinoma. The use of pazopanib in the management of malignancies has increased over recent years, with more patients at risk of developing medication-related osteonecrosis of the jaw (MRONJ). This paper presents the first case report of MRONJ associated with pazopanib monotherapy. A 59-year-old man was referred to the dental clinic with complaints of dysphagia and dysgeusia. The patient was prescribed pazopanib (400 mg) daily following surgical treatment and chemotherapy for metastatic renal cell carcinoma. He had undergone extraction of the maxillary left second premolar nine weeks previously. Intraoral examination revealed exposed necrotic bone, which was treated effectively with leukocyte and platelet-rich fibrin (LPRF). The patient was followed up for 150 days after dental treatment with no signs of relapse.

RESUMEN: Pazopanib, un agente antiangiogénico, ha mostrado resultados prometedores en el control del crecimiento tumoral y las metástasis en pacientes con carcinoma de células renales. El uso de pazopanib en el tratamiento de las neoplasias malignas ha aumentado en los últimos años, con más pacientes en riesgo de desarrollar osteonecrosis de la mandíbula relacionada con la medicación (MRONJ). Este artículo presenta el primer reporte de caso de MRONJ asociado con la monoterapia con pazopanib. Un hombre de 59 años fue remitido a la clínica dental con quejas de disfagia y disgeusia. Al paciente se le prescribió pazopanib (400 mg) al día tras tratamiento quirúrgico y quimioterapia por carcinoma metastásico de células renales. Había sido sometido a extracción del segundo premolar superior izquierdo nueve semanas antes. El examen intraoral reveló hueso necrótico expuesto, que fue tratado eficazmente con leucocitos y fibrina rica en plaquetas (LPRF). El paciente fue seguido durante 150 días después del tratamiento dental sin signos de recidiva.

Terapia fotodinámica en el tratamiento de la osteonecrosis inducida por fármacos: reporte de un caso / Photodynamic therapy in the treatment of drug-induced osteonecrosis: a case report

El objetivo del presente caso fue investigar los beneficios de la terapia fotodinámica (TFD) en ciclos de aplicación como método de tratamiento de la osteonecrosis inducida por fármacos (ONMRM), reportando el caso de un paciente masculino de 75 años, blanco, con diagnóstico de neoplasia maligna renal con metástasis pulmonares y óseas en tratamiento con malato de sunitinib y denosumab. El paciente fue derivado para evaluación dental en un consultorio habilitado para atender pacientes con necesidades especiales, en la ciudad de Salvador-Ba. En el examen intraoral se observaron áreas de tejido óseo expuesto y necrótico en la mandíbula (cara medial) a ambos lados, próximas a la región molar, con aspecto ulcerativo, de tres milímetros de diámetro, y la hipótesis diagnóstica fue de ONMRM en estadio 2. Se inició el protocolo de aplicación de 20 ciclos de TFD, como única forma de tratamiento, en dos sesiones semanales con terapia láser preventiva para la mucositis oral. Durante y al final del tratamiento fue posible el secuestro óseo necrótico, promoviendo la bioestimulación y la curación locorregional, sin manifestación clínica de la patología durante el mantenimiento. Con base en este informe y la evidencia en la literatura científica, se cree que se deben promover los ensayos clínicos, debido a los registros prometedores y efectivos del tratamiento que la terapia hace posible.

The main of this case was to investigate the benefits of photodynamic therapy (PDT) in application cycles as a method of treatment of medication-related osteonecrosis of the jaw (MRONJ), reporting the case of a 75-year-old white male patient with a diagnosis of renal malignancy with lung and bone metastases treated with sunitinib malate and denosumab. The patient was referred for dental evaluation in an office set up to attend patients with special needs, in the city of Salvador-Ba. In the intraoral examination, areas of exposed and necrotic bone tissue were observed in the mandible (medial aspect) on both sides, close to the molar region, with an ulcerative appearance, three millimeters in diameter, and the diagnostic hypothesis was stage 2 ONMRM The application protocol of 20 PDT cycles was started, as the only form of treatment, in two weekly sessions with preventive laser therapy for oral mucositis. During and at the end of the treatment, necrotic bone sequestration was possible, promoting biostimulation and locoregional healing, without clinical manifestation of the pathology during maintenance. Based on this report and the evidence in the scientific literature, it is believed that clinical trials should be promoted, due to the promising and effective records of the treatment that the therapy makes possible.

Morphological evaluation of dental diseases in Parion chamber tomb (OM 5) Roman people / Evaluación morfológica de enfermedades dentales en la tumba de la cámara de Parion (OM 5) del pueblo romano

SUMMARY: Most of the dental diseases occur due to tooth or jaw morphology or nutritional habits. Anatomical differences in the teeth and jaws of men and women can cause different dental diseases between the sexes. In this study, 33 skeletons obtained from the excavation of the ancient city of Parion, which are dated to the late Roman period, were examined. Dental diseases and possible causes were investigated on a total of 33 skeletons. In the evaluations, it was evaluated that some diseases were caused by the difference between the sexes, while some were classified as nutritional diseases. The rates of tooth decay are different between men and women with Parion. It has been determined that the most important reason for this is the different morphological structure of the jaws and teeth, but the nutritional differences also cause this. Other dental and jaw diseases were also evaluated in the Parion population.

RESUMEN: La mayoría de las enfermedades dentales se deben a la morfología de los dientes o la mandíbula o a los hábitos nutricionales. Las diferencias anatómicas en los dientes y las mandíbulas de hombres y mujeres pueden causar diferentes enfermedades dentales entre los sexos. En este estudio, se examinaron 33 esqueletos obtenidos de la excavación de la antigua ciudad de Parion, que datan del período romano tardío. Se investigaron las enfermedades dentales y las posibles causas en un total de 33 esqueletos. En las evaluaciones, se determinó que algunas enfermedades fueron causadas por la diferencia entre los sexos, mientras que otras fueron clasificadas como enfermedades nutricionales. Además se encontraron diferentes estimaciones de caries entre hombres y mujeres. Se analizó que la razón más importante de esto es la diferencia de la estructura morfológica de los maxilares y los dientes, sin embargo las diferencias nutricionales también es un factor que se debe considerar. Se evaluaron además, otras enfermedades dentales y de la mandíbula en la población de Parion.

Caracterización clínico-terapéutica de pacientes diagnosticados con Osteonecrosis en los maxilares relacionada con medicación / Clinical and therapeutic characterization of patients diagnosed with medication-related osteonecrosis of the jaws

Introducción: La osteonecrosis en los maxilares por medicación es una afección asociada al tratamiento con bifosfonatos, antireabsortivos y antiangiogénicos. Objetivo: Caracterizar clínica y terapéuticamente los pacientes diagnosticados de Osteonecrosis en los Maxilares relacionada con medicación. Material y Método: Se realizó una serie de casos de 19 pacientes, la totalidad de los diagnosticados con la entidad en el Servicio de Cirugía Maxilofacial. Facultad de Estomatología Raúl González Sánchez, enero 2018-enero 2019. Se identificó severidad, factores de riesgo y se estandarizó tratamiento que incluyó la curación con aceite ozonizado y la aplicación de láser infrarrojo. Se evaluó el tratamiento a los 90 días. Se operacionalizaron las variables: sexo, tipo de medicación, vía y tiempo de administración, localización y evaluación al tratamiento. Resultados: La edad promedio de los pacientes fue 69±8,5 años, un 52,63 por ciento fueron masculinos, el zolendronato fue el agente mas asociado en el 78,95 por ciento de los casos, la enfermedad periodontal fue el factor local preponderante (57,89 por ciento), la localización mandibular postero lateral y el estadio evolutivo 2 predominaron en el 63,16 por ciento y 52,63 por ciento de las lesiones. El 78,94 por ciento de los casos presentó evolución satisfactoria a los 90 días. Conclusiones: La medicación con bifosfosfonatos parenterales predominantemente con el zolendronato, fue la causa principal de las osteonecrosis, las cuales prevalecieron en el sector postero lateral de mandíbula y con el estadio 2. La variante de tratamiento de curación con aceite ozonizado e irradiación con láser fue la más implementada. Los valores de lesiones resueltas y mejoradas a los 90 días fueron satisfactorios(AU)

Introduction: Medication-related osteonecrosis of the jaws is an affection associated with the treatment with bisphosphonates, antiresorptive agents or antiangiogenic medications. Objective: To perform a clinical and therapeutic characterization of patients with the diagnosis of medication-related osteonecrosis of the jaws. Material and Method: A case series of a total of 19 patients with the diagnosis of medication-related osteonecrosis of the jaws was carried out in the Department of Dental and Maxillofacial Surgery of ¨Raúl González Sánchez¨ Dental School of Havana from January 2018 to January 2019. The severity and risk factors were identified and the treatment including the healing with ozone oil and the application of infrared laser was standardized. The patients were evaluated in the 90 days after treatment. The operationalization of variables included: sex, type of medications, ways and time of administration, localization, and evaluation of treatment. Results: The average age of patients was 69±8,5 years and 52,63 percent of them were male. Zolendronate was the most associated agent in 78,95 percent of cases. Periodontal disease was the most identified local factor (57, 89 percent). The posterolateral area of the mandible and stage 2 disease evolution predominated in 63,16 percent and 52, 63 percent of lesions, respectively. Also 78, 94 percent of cases had a satisfactory evolution in the 90 days after treatment. Conclusions: The administration of intravenous bisphosphonates, particularly Zolendronate, was the main cause of osteonecrosis. These lesions were mainly located in the posterior lateral area of the mandible and presented stage 2 disease evolution. Healing with ozone oil and application of infrared laser was the most implemented alternative treatment. The values of resolved and improved lesions were satisfactory in the 90 days after treatment(AU)

Evaluation of hyperbaric oxygen therapy for the osteoradionecrosis of the jaws: Meta-analysis / 华西口腔医学杂志

OBJECTIVES@#This study was performed to investigate the effects of hyperbaric oxygen and other approaches for treating the osteoradionecrosis of the jaws (ORNJ) systematically.@*METHODS@#According to the preset inclusion and exclusion criteria, randomized controlled trials and cohort studies on hyperbaric oxygen in the treatment of ORNJ were screened, and foreign language databases such as PubMed, EMBASE, and Cochrane library were searched via a computer; Chinese databases such as CNKI, VIP, Wanfang data, and CBM were searched from the established database to September 2020. Relevant books were searched manually to collect all literatures on the efficacy of hyperbaric oxygen and its related therapies in ORNJ treatment. Two researchers were independent and mutually blind, the papers were selected, data were collected, and the bias risk was evaluated. If any difference was detected, it would be decided by discussion or arbitrated by a third party. The data related to the efficacy of hyperbaric oxygen and its related therapy in the treatment of the ORNJ were extracted, and the Revman5.4 software was used for Meta-analysis. In case of large heterogeneity, sensitivity analysis was performed. A funnel chart was used to evaluate possible publication bias qualitatively.@*RESULTS@#Four randomized controlled trials and seven cohort studies were included in Meta-analyses. In ORNJ treatment, no significant differences between the group subjected to hyperbaric oxygen and both surgery and antibiotics and the group that underwent both surgery and antibiotics (RR=1.16, 95%CI: 0.86~1.58, @*CONCLUSIONS@#Hyperbaric oxygen therapy cannot replace surgery and antibiotic therapy. Hyperbaric oxygen therapy is not superior to antibiotics and antifibrotic drugs, but the benefits of antifibrotic drugs should be further explored.

Mechanism, prevention, and treatment for medication-related osteonecrosis of the jaws / 华西口腔医学杂志

The morbidity rate of medication-related osteonecrosis of the jaws (MRONJ) increased rapidly in recent years. Thusfar, the mechanism of MRONJ has no consensus. The possible mechanisms may include bone remodeling inhibition theory, angiogenesis inhibition theory, oral microorganism infection theory, immunosuppression theory, cytotoxicity-targeted oral epithelial cells, microcrack formation of maxillary or mandibular bone, and single nucleotide polymorphism. However, the efficacy of prevention and treatment based on a single mechanism is not ideal. Routine oral examination before MRONJ-related drug treatment, treatment of related dental diseases, and regular oral follow-up during drug treatment are of great significance for the prevention of MRONJ. During the treatment of MRONJ, the stage of MRONJ must be determined accurately, treatment must be standardized in accordance with the guidelines, and personalized adjustments must be made considering the specific conditions of patients. This review aimed to combine the latest research and guidelines for MRONJ and the experiences on the treatment of MRONJ in the Maxillofacial Surgery Department of West China Hospital of Stomatology, Sichuan University, and discuss the strategies to improve the clinical process.

Multifocal eosinophilic granuloma of the jaws with long-term follow-up: a case report / 华西口腔医学杂志

Eosinophilic granuloma, a rare disease, has various clinical manifestations and no specific X-rays features and is thus easily misdiagnosed. This paper reports a case of multifocal eosinophilic granuloma of jaw with long-term follow-up. The patient initially presented with periodontal tissue destruction.The diagnosis, treatment and prognosis of multifocal eosinophilic granuloma of jaw were discussed in combination with the literature to alert this disease in clinical practice.

Osteonecrosis maxilar relacionada con medicamentos en pacientes oncológicos con metástasis óseas: resolución de dos casos / Medication-related osteonecrosis of the jaw in oncological patients with bone metastases: resolution of two cases

La osteonecrosis maxilar relacionada con medicamentos (ONMM) es una patología de características clínicas objetivas con signo-sintomatología patognomónica. El criterio clínico aceptado es la presencia de hueso necrótico expuesto y visible sobre el reborde óseo maxilar que no ha cicatrizado luego de 8 semanas, en pacientes con antecedentes de tratamiento antirresortivo. La denominación "relacionada con medicamentos" se utiliza por el creciente número de casos asociados con otros fármacos antirresortivos como denosumab y con terapias antiangiogénicas, más allá de la conocida relación con bifosfonatos.Si bien la incidencia de ONMM en pacientes tratados por osteopatías metabólicas es muy baja, la situación se torna más compleja en pacientes oncológicos con altas dosis de antirresortivos para tratamiento de metástasis ósea. Varios in-formes de casos describen cuadros de ONMM en pacientes con cáncer que reciben terapias dirigidas, específicamente TKI (inhibidores de tirosina quinasa) y anticuerpos monoclonales-VEGF (anticuerpos dirigidos al factor de crecimiento del endotelio vascular). La ONMM afecta negativamente la calidad de vida del paciente oncológico y produce comorbilidad significativa. Resulta imperioso identificar a los pacientes en riesgo y diseñar un protocolo de atención odontológica específico para estos casos. En este artículo se presentan dos casos de ONMM asociado con altas dosis de denosumab y administración simultánea de anticuerpos monoclonales específicos para el tratamiento del cáncer. Ambos casos sorprenden por la prematura instalación de la necrosis y su cuadro insidio-so. El protocolo de tratamiento descripto permitió controlar el cuadro inicial, limitar el avance de la lesión, asegurar el control del dolor y la infección, y finalmente, la curación total de la lesión. (AU)

Medication-related osteonecrosis of the jaws (MRONJ) is a pathology with objective clinical characteristics, with pathognomonic signs and symptoms. The accepted clinical criterion is the presence of exposed and visible necrotic bone on the maxillofacial region that has not healed after 8 weeks, in patients with history of antiresorptive treatment.The name "medication-related" is justified by the growing number of cases associated with other antiresorptive drugs such as denosumab and antiangiogenic therapies, beyond the known relationship with bisphosphonates. Although the incidence of MRONJ in patients treated for metabolic osteopathies is very low, the situation becomes more complex in cancer patients who receive high doses of antiresorptives for the treatment of skeletal metastases. Several case reports describe the presence of MRONJ in cancer patients receiving targeted therapies, specifically TKI (tyrosine kinase inhibitors) and monoclonal antibodies-targeting VEGF (vascular endothelial growth factor). MRONJ negatively affects the quality of life in cancer patients and produces significant comorbidity. It is imperative to identify patients at risk and design a specific dental care strategy for these cases.In this article, we present two cases of MRONJ associated with high doses of Denosumab and simultaneous administration of specific monoclonal antibodies. Both cases are surprising due to premature onset of necrosis. The described treatment strategies made it possible to control the initial symptoms, limit the lesion progression, ensure pain and infection control, and finally, the total healing of the lesion. (AU)

Efetividade da terapia fotodinâmica antimicrobiana utilizando butil azul de toluidina e laser de baixa potência na prevenção da osteonecrose dos maxilares associada à terapia medicamentosa / Effectiveness of antimicrobial photodynamic therapy using butyl toluidine blue and low-level laser in preventing the occurrence of medicationrelated osteonecrosis of the jaws

O presente estudo teve como objetivo avaliar a efetividade e a segurança do emprego de múltiplas sessões de aPDT, utilizando o butil azul de toluidina (BuAT) e a irradiação com laser de baixa potência (LBP), no sítio de extração dental de ratas com os principais fatores de risco para a ocorrência da osteonecrose dos maxilares associada à terapia medicamentosa (ONM-M). Vinte e oito ratas senescentes foram distribuídas em quatro grupos experimentais: VEI, VEI-aPDT, ZOL e ZOL-aPDT. O protocolo de tratamento teve duração de 7 semanas. Um dia antes do início deste protocolo foi instalada uma ligadura de algodão ao redor do primeiro molar inferior esquerdo para indução da periodontite experimental (PE). Nos grupos VEI e VEI-aPDT, as ratas receberam injeções intraperitoneais de 0,45ml de solução de cloreto de sódio 0,9% (veículo) a cada três dias. Nos grupos ZOL e ZOL-aPDT, as ratas receberam 0,45ml do veículo acrescido de 100µg/Kg do zoledronato a cada três dias. Após três semanas do início do protocolo de tratamento a ligadura foi removida e foi realizada a exodontia do primeiro molar inferior esquerdo. Nos grupos VEI e ZOL não foi efetuado nenhum tratamento local no sítio de extração dental. Nos grupos VEI-aPDT e ZOL-aPDT foram realizadas sessões de aPDT aos 0, 2, e 4 dias pós exodontia. Para a aPDT depositouse sobre o sítio de extração dental 300µl de BuAT (concentração: 0,5mg/ml; tempo de pré-irradiação, 60s) em seguida foi realizada a irradiação com laser de baixa potência (laser: InGaAIP; 660nm; 35mW; 74,2J/cm²; 60s) emissor: InGaAlP; comprimento de onda: 660 nm, laser visível - vermelho; potência: 35 mW; densidade energética por ponto: 74,2 J/cm2 ; tempo de aplicação: 60s). Decorridos 28 dias pós-operatórios foi realizada a eutanásia. As hemimandíbulas foram devidamente processadas para assegurar que no sítio de extração dental fossem efetuadas: 1) análise clínica; 2) análise histológica da reparação tecidual; 3) análise histométrica da Porcentagem de Tecido Ósseo Neoformado (PTOnf); 4) análise histométrica da Porcentagem de Tecido Ósseo Não Vital (PTOnv) e; análise imunoistoquímica de células TRAPpositivas. Os dados foram submetidos à análise estatística com nível de significância de 5%. Os grupos ZOL e ZOL-aPDT apresentaram menor quantidade de células TRAP-positivas quando comparados com os grupos VEI e VEI-aPDT. O grupo ZOL apresentou grande comprometimento do processo de reparação tecidual, condizentes com um quadro de ONM-M. Os grupos VEI, VEI-aPDT e ZOL-aPDT apresentaram um processo de reparação tecidual favorável do sítio de extração dental. No grupo ZOL a PTOnf no sítio de extração dental se mostrou menor que nos grupos VEI, VEI-aPDT e ZOL-aPDT. No grupo ZOL a PTOnv se mostrou maior que nos grupos VEI, VEIaPDT e ZOL-aPDT. No grupo ZOL-aPDT a PTOnv se apresentou maior que nos grupos VEI e VEI-aPDT. O emprego de múltiplas sessões de aPDT, utilizando o BuAT e LBP, no sítio de extração dental de ratas senescentes tratadas com alta dose de zoledronato se mostrou uma estratégia terapêutica segurança e efetiva para evitar a ocorrência da ONM-M pós exodontia(AU)

The present study aimed to evaluate the effectiveness and safety of using multiple aPDT sessions, using butyl toluidine blue (BuTB) and low-level laser irradiation (LLL), at the dental extraction site of rats with the main risk factors for the occurrence of medication-related osteonecrosis of the jaws (MRONJ). Twenty-eight senescent rats were distributed in four experimental groups: VEH, VEH-aPDT, ZOL and ZOL-aPDT. The treatment protocol lasted 7 weeks. One day before the beginning of this protocol, a cotton ligature was installed around the mandibular first molar left to induce experimental periodontitis (EP). In the VEH and VEH-aPDT groups, the rats received intraperitoneal injections of 0.45 ml of 0.9% sodium chloride solution (vehicle) every three days. In the ZOL and ZOL-aPDT groups, the rats received 0.45 ml of the vehicle plus 100 µg / Kg of zoledronate every three days. Three weeks after the beginning of the treatment protocol, the ligature was removed and extraction of the mandibular first molar left was performed. In the VEH and ZOL groups, no local treatment was performed at the tooth extraction site. In the VEH-aPDT and ZOL-aPDT groups, aPDT sessions were performed at 0, 2, and 4 days after extraction. For aPDT, 300µl of BuTB was deposited on the dental extraction site (0.5mg / ml; pre-irradiation time, 60s), followed by irradiation with low-level laser (laser: InGaAIP; 660nm; 35mW; 74.2J / cm²; 60s). After 28 postoperative days, euthanasia was performed. The hemimandibles were properly processed to ensure that at the tooth extraction site: 1) clinical analysis; 2) histological analysis of tissue repair; 3) histometric analysis of the Percentage of Neoformed Bone Tissue (PNFBT); 4) histometric analysis of the Percentage of NonVital Bone Tissue (PNVBT) and; immunohistochemical analysis of TRAP-positive cells. The data were submitted to statistical analysis with a 5% significance level. The ZOL and ZOL-aPDT groups showed less TRAP-positive cells when compared with the VEH and VEH-aPDT groups. The ZOL group showed great compromise in the tissue repair process, consistent with MRONJ. The groups VEH, VEH-aPDT and ZOL-aPDT presented a favorable tissue repair process at the dental extraction site. In the ZOL group, the PNFBT at the tooth extraction site was lower than in the VEH, VEH-aPDT and ZOL-aPDT groups. In the ZOL group, PNVBT was higher than in the VEH, VEHaPDT and ZOL-aPDT groups. In the ZOL-aPDT group, PNVBT was higher than in the VEH and VEH-aPDT groups. The use of multiple aPDT sessions, using BuTB and LLL, at the dental extraction site of senescent rats treated with a high dose of zoledronate proved to be a safe and effective therapeutic strategy to prevent the occurrence of MRONJ after tooth extraction(AU)

Paget's disease of the jaws: Histopathological features of a series of 31 cases / Enfermedad de Paget en los maxilares. Características histopatológicas de una serie de 31 casos

ABSTRACT The aim of the present study was to analyze the histopathological features of Paget's disease of the jaws observed in a series comprising 31 cases. The study comprised all cases of Paget's disease of the jaws filed in the archives of the Surgical Pathology Laboratory of the Oral Pathology Department, School of Dentistry, University of Buenos Aires, between 1960 and 2018. Their microscopic features were evaluated, and available clinical data and radiographic studies were analyzed. Paget's disease of the jaws accounted for 0.05% of retrieved oral-maxillofacial pathologies. Microscopically, all cases showed lamellar bone trabeculae with the characteristic mosaic pattern. Twenty cases (64%) showed osteoblastic-osteoclastic activity, and all showed areas of necrosis. Cemento-osseous trabeculae were observed in 15 cases (48%), and cementicles were observed in 13 (42%). Osteomyelitis was seen in 11 cases (35%), all of which showed cemento-osseous trabeculae with a mosaic structure, sclerosis and necrosis, and chronic inflammation with abscess formation. Mean age was 61 years (44-85 years); 19 cases were women. Localization was the maxilla in 13 cases (42%), and the disease involved other skeletal bones in five cases. To our knowledge, this is the largest series of Paget's disease of the jaws reported to date. Paget's disease is infrequent in the jaws and has distinct histopathological features that not only differ from those observed at other skeletal sites but also require differential diagnosis from other pathologies affecting the jaws exclusively.

RESUMEN El objetivo del presente trabajo fue analizar las características histopatológicas de la enfermedad de Paget en los maxilares en una serie de 31 casos. El estudio comprendió todos los casos de enfermedad de Paget de los maxilares provenientes del Laboratorio de Patología Quirúrgica de la Cátedra de Anatomía Patológica de la Facultad de Odontología de la Universidad de Buenos Aires, entre 1960 y 2018. Se evaluaron las características microscópicas y se analizaron los datos clínicos y estudios radiográficos disponibles. La enfermedad de Paget en los maxilares representó el 0,05% de las patologías buco-maxilofaciales. Microscópicamente, todos los casos mostraron trabéculas óseas laminares con el característico patrón en mosaico. Veinte casos (64%) mostraron actividad osteoblástica-clástica y todos los casos mostraron necrosis focal. En 15 casos (48%) las trabéculas presentaron aspecto cemento-óseo y en 13 casos (42%) se observaron cementículos. Once casos (35%) presentaron cuadros osteomielíticos y todos ellos mostraron trabéculas cemento-óseas con estructura en mosaico, esclerosis y necrosis, e infiltrado inflamatorio crónico con formación de abscesos. La media de edad fue 61 años (44- 85 años), y 19 fueron mujeres. Trece casos (42%) se localizaron en maxilar superior y 5 casos presentaron compromiso de otros huesos. A nuestro entender, esta es la serie más grande de enfermedad de Paget en los maxilares reportada hasta la fecha. La enfermedad de Paget es poco frecuente en los maxilares y presenta características histopatológicas que además de ser diferentes a las observadas en otros sitios del esqueleto plantean el diagnóstico diferencial con otras entidades que se presentan exclusivamente en los maxilares.

Fundamentos de elección terapéutica: osteonecrosis maxilar asociada a drogas antirresortivas (MRONJ) / Fundamentals of therapeutic choice: anti-resorptive drug-related maxillary osteonecrosis (MRONJ)

La acción terapéutica favorable que los antirresortivos (bifosfonatos BPs, denosumab DS) y drogas antiangiogénicas ocasionan en el tejido óseo en aquellos pacientes que presentan como causa etiológica cáncer o discrasias óseas incluyen hipercalcemias malignas o ­si requieren el consumo de dicha droga a baja concentración­ como ser: osteoporosis, osteopenia, enfermedad de Paget, displasia fibrosa, Osteogénesis Imperfecta. (1) La presente actualización pretende relacionar el tratamiento odontológico con prescripción crónica y drogas antirresortivas, para lo cual American Association of Oral and Maxillofacial Surgeons AAOMS: define el concepto de Osteonecrosis Maxilar Asociada a drogas Antirresortivas (MRONJ) como: «Área ósea necrótica expuesta al medio bucal con más de ocho semanas de permanencia, en presencia de tratamiento crónico con bifosfonatos en ausencia de radioterapia en cabeza y cuello¼. La AAOMS estableció los siguientes grupos de acuerdo con sus características clínicas en 4 estadios (0, 1 ,2 y 3) de acuerdo con el aspecto clínico y radiológico de la lesión osteonecrótica. Estadío 0: lesión osteonecrótica sin evidencia de hueso necrótico en pacientes bajo consumo de drogas antirresortivas. Estadío 1: lesión osteonecrótica con signos clínicos y ausencia de sintomatología clínica. Estadío 2: lesión osteonecrótica con signo y sintomatología clínica evidente. Estadío 3: lesión osteonecrótica con signo y sintomatología evidente que compromete a estructuras nobles: fracturas patológicas, anestesia del nervio dentario inferior, comunicación buco-nasal, comunicación buco-sinusal, fístulas cutáneas (2) (AU)

It is known the favourable action which antiresorptive (Bisphosphonates BPs, Denosumab: DS) and Antiangiogenic drugs produce in bone tissue. High concentrations are primarily used as an effective treatment in the management of cancer-related disorders, including hypercalcemia of malignant. Besides, low concentrations are used for other metabolic bone diseases including Osteoporosis, Osteopenia, Paget's Disease, Fibrous Dysplasia, Imperfect Osteogenesis. (1) The update relate relationship between dentistry and chronic treatment with antiresorptive drugs. According to the American Association of Oral and Maxillofacial Surgeons (AAOMS), MRONJ is defined as exposed or necrotic bone in the maxillofacial region that has persisted for more than 8 weeks in association with current or previous BPs or DS therapy and with a lack of head and neck radiotherapy. AAOMS divided the MRONJ into 4 stages (0,1, 2 and 3) according to the clinical and radiological aspect of the osteonecrotic lesion: Stage 0: osteonecrotic lesion without sign-pathognomonic evidence of osteonecrosis. Stage 1: osteonecrotic lesion with clinical signs and absence of clinical symptoms. Stage 2: osteonecrotic lesion with sign and evident clinical symptoms. Stage 3: osteonecrotic lesion with signs and evident symptoms that involve noble structures: pathological fractures, anaesthesia of the lower dental nerve, oral-nasal communication, oral-sinus communication, skin fistulas (2) (AU)

Survival of short dental implants in atrophied jaw: a systematic review

AIM: Short implants are manufactured for use in atrophic regions of the jaw. Therefore, the current does not sufficiently reveal a direct correlation between the impact of implant length on implant survival. The purpose of this systematic review was to compile the evidence of short implant survival in atrophied jaws. METHODS: Electronic and manual literature searches were performed by two independent reviewers in several databases, including MEDLINE, EMBASE, and Cochrane Oral Health Group Trials Register, for articles up to September 2015 using the following terms in some combinations: "short implant", "mandible/atrophied jaws", and "implant survival/ survival rate/ survival analysis". RESULTS: The 19 included studies present in average 5.5 years (range 1.0-20.0 years) follow-up and 96.1% (range 73.4-100.0 percent) survival rate of the short implants in atrophied mandibular. CONCLUSIONS: This systematic review found evidences regarding to safety of short implant placement in atrophied jaws although stronger evidence is essential to confirm this finding.

Knowledge, attitudes, and practices of dentists in Colombia regarding bisphosphonate-induced osteonecrosis of the jaws / Conhecimento, atitudes e práticas de dentistas na Colômbia sobre osteonecrose dos maxilares induzida por bisfosfonatos / Conocimientos, actitudes y prácticas de los odontólogos en Colombia respecto a la osteonecrosis de las mandíbulas inducida por bisfosfonatos

Abstract Introduction and objective: In order to provide proper dental management to patients who are under bisphosphonate therapy it is of critical importance that dentists perform a good anamnesis, a comprehensive clinical examination to asses for possible risk factors for bisphosphonate-induced osteonecrosis of the jaws (BIONJ). Although this issue has been explored in other parts of the world, in Colombia there is currently no scientific evidence to support it. Thus, the aim of this study was to compare knowledge, attitudes, and practices (domains) of general and specialist dentists regarding BIONJ. Materials and methods: Paper/online surveys that included questions about knowledge, attitudes, and practices regarding BIONJ were distributed and completed by 228 general dentists and 114 dental specialists in Colombia. Student's t-test was used to determine statistical difference between groups of dentists (P < 0.05). Results: The attitudes domain was removed from the analysis as it did not meet statistical criteria. Overall rate of BIONJ knowledge was 55.8%, being 65.3% and 50.7% for specialists and general dentists respectively. The difference between these groups was statistically significant (P = 0.0004). Overall rate of adequate practices was 38.4%, being 44.6% for dental specialists, and 35.1% for general dentists. The difference between these groups was statistically significant (P = 0.023). Conclusion: The level of knowledge and good practices regarding BIONJ in Colombia was greater and better in dental specialists than in general dentists. Those with higher knowledge scores suggested greater educational efforts to spread knowledge among dentists about BIONJ.

Resumen Introducción y objetivo: Para proporcionar un tratamiento odontológico adecuado a los pacientes que están bajo terapia con bisfosfonatos, es importante que los odontólogos realicen una buena anamnesis, un examen clínico integral para evaluar los posibles factores de riesgo de osteonecrosis de las maxilares inducida por bisfosfonatos (BIONJ). Aunque este tema ha sido explorado en otras partes del mundo, en Colombia actualmente no hay evidencia científica que lo respalde. Así, el objetivo de este estudio fue comparar el conocimiento, las actitudes y prácticas (dominios) de los odontólogos generales y especialistas con respecto a la BIONJ. Materiales y métodos: Encuestas físicas y digitales que incluían preguntas sobre conocimientos, actitudes y prácticas con respecto a BIONJ fueron distribuidas y llenadas por 228 odontólogos generales y 114 especialistas en Colombia. La prueba t de Student se usó para determinar la diferencia estadística entre grupos de odntólogos (P <0.05). Resultados: El dominio de actitudes se eliminó del análisis ya que no cumplía con los criterios estadísticos. La tasa general de conocimiento de BIONJ fue de 55,8%, siendo 65,3% y 50,7% para especialistas y odontólogos generales, respectivamente. La diferencia entre estos grupos fue estadísticamente significativa (P = 0,0004). La tasa general de prácticas decuadas fue del 38.4%, siendo 44.6% para los especialistas y 35.1% para los odontólogos generales. La diferencia entre estos grupos fue estadísticamente significativa (P = 0.023). Conclusión: El nivel de conocimiento y buenas prácticas con respecto a BIONJ en Colombia fue mayor y mejor en los odontólogos especialistas que en los generales. Aquellos con puntajes altos de conocimiento sugirieron mayores esfuerzos educativos en la difusión del conocimiento sobre BIONJ entre los odontólogos generales.

Resumo Introdução e objetivo: A fim de fornecer tratamento odontológico adequado aos pacientes sob terapia com bifosfonatos, é de importância crítica que os dentistas realizem uma boa anamnese, um exame clínico abrangente para avaliar possíveis fatores de risco para osteonecrose dos maxilares induzida por bisfosfonatos (BIONJ). Embora essa questão tenha sido explorada em outras partes do mundo, atualmente na Colômbia não há evidências científicas para apoiá-la. O objetivo deste estudo foi comparar conhecimentos, atitudes e práticas (domínios) de dentistas gerais e especialistas em osteonecrose dos maxilares induzida por bisfosfonatos (BIONJ). Materiais e métodos: Pesquisas em papel / on-line que incluíam perguntas sobre conhecimentos, atitudes e práticas relacionadas ao BIONJ foram distribuídas e concluídas por 228 dentistas gerais e 114 especialistas em odontologia na Colômbia. O teste t de Student foi utilizado para determinar a diferença estatística entre os grupos de dentistas (P <0,05). Resultados: O domínio de atitudes foi retirado da análise por não atender aos critérios estatísticos. A taxa geral de conhecimento do BIONJ foi de 55,8%, sendo 65,3% e 50,7% para especialistas e dentistas, respectivamente. A diferença entre esses grupos foi estatisticamente significante (P = 0,0004). A taxa geral de práticas adequadas foi de 38,4%, sendo 44,6% para especialistas em odontologia e 35,1% para dentistas em geral. A diferença entre esses grupos foi estatisticamente significante (P = 0,023). Conclusão: O nível de conhecimento e boas práticas sobre o BIONJ na Colômbia foi maior e melhor em especialistas em odontologia do que em dentistas em geral. Aqueles com maior pontuação de conhecimento sugeriram maiores esforços educacionais para difundir conhecimento entre os dentistas sobre o BIONJ.

Análise do processo de reparo alveolar em camundongos fêmeas senescentes 129/Sv-WT e 129/Sv 5-LOKO sob terapia com bifosfonato de alta potência / Alveolar bone repair of 129/Sv WT and 129/Sv 5LOKO female senescent mice under therapy with high potency bisphosphonate

O processo de senescência acarreta uma série de modificações fisiológicas com declínio das funções das atividades celulares e sistêmicas que se manifestam de maneira mais importante na população feminina pelo evento da menopausa, como a osteoporose. A fim de se minimizar tais efeitos, há a possibilidade de se utilizar medicamentos que diminuem o processo de remodelação óssea como os bifosfonatos nitrogenados (BF). Entretanto, o uso dessas drogas está intimamente relacionado ao desenvolvimento de osteonecrose dos maxilares (OM), principalmente quando associado a outros fatores de risco como as cirurgias bucais. Sabe-se que fisiologicamente a dinâmica do tecido ósseo depende também de eicosanóides derivados do metabolismo do ácido araquidônico (AA), como as enzimas cicloxigenase (COX) e 5 lipoxigenase (5LO). Deste modo, o objetivo do presente trabalho foi analisar o efeito BF ácido zoledrônico (ZL) e sua relação com o desenvolvimento da OM em camundongos fêmeas senescentes 129/Sv com e sem modificação genética para a enzima 5LO. Para tanto, foram utilizados 40 camundongos fêmeas senescentes 129/Sv, sendo 20 WT e 20 com alteração no gene 5LO (129 Alox5tm1Fun/J) (5LOKO), divididas em grupos: WT, tratadas com 0,01 ml de solução salina 0,9% estéril (SS) via intraperitoneal (IP) e ZL, tratadas com 250µg/Kg de ácido zoledrônico (ZL) IP diluído em solução salina estéril, ambas administradas 1 vez/semana por 7 semanas. Os grupos foram compostos por 5 animais cada (WT Controle ­ 7 e 21dias, WT ZL ­ 7 e 21 dias, 5LOKO Controle ­ 7 e 21 dias, 5LOKO ZL ­ 7 e 21dias), sendo as maxilas coletadas para análises em microCT, histopatológica, birrefringência, técnica imunohistoquímica e histomorfométricas. De modo geral, a microCT revelou deficiência significativa na microarquitetura óssea nos animais WT ZL em comparação com os demais. Do mesmo modo, a partir da análise histopatológica e de birrefringência da matriz colagenosa, observou-se padrão compatível com o desenvolvimento de OM no grupo WT ZL, com presença de infiltrado inflamatório intenso, atraso na neoformação óssea, presença de fraturas patológicas, e deficiência da matriz colagenosa e de células Runx-2+, TRAP+ e F4/80+. Os animais 5LOKO ZL apresentaram alterações compatíveis com atraso no processo de reparo especialmente no período de 7 dias, com menor quantidade de células Runx-2+ em comparação com o grupo 5LOKO Controle e pela qualidade da matriz óssea colagenosa com menor quantidade de fibras do espectro vermelho neste período, se igualando, porém, aos 21 dias. Deste modo, concluiu-se que o processo de reparo em camundongos fêmeas senescentes da linhagem 129/Sv WT e 5LOKO associados ao uso do BF ZL ocorreu de modo distinto, levando a quadro de OM nos animais WT e atraso nos animais 5LOKO, sem sinais histopatológicos que caracterizassem a doença. Deste modo, a inibição da enzima 5LO parece influenciar de maneira positiva o processo de reparo ósseo intramembranoso alveolar, mesmo na presença de fenótipo esqueletal osteopetrótico, sugerindo outros fatores relacionados à droga que favoreçam o desenvolvimento da OM no presente modelo animal(AU)

Senescence brings a number of physiological modifications with the decrease of cell and systemic activities and function that manifest in an important way in female population due to the event of menopause, as osteoporosis. In order to diminish these effects, there is the possibility of taking medication that decrease bone remodeling process, as the bisphosphonates containing nitrogen (BF). However, the use of these drugs is intimate related with the development of the osteonecrosis of the jaws (ON), especially when associated to other risk factors as oral surgery. It is known that physiologically, the dynamics of bone tissue also depends on the eicosanoids derivate from the arachidonic acid metabolism (AA), such as cyclooxygenase (COX) and 5 lipoxygenase (5LO) enzymes. In this way, the aim of the present study was to analyze the effects of the BF zoledrônico acid (ZL) and its relation with de development of ON in 129/SV old female mice with or without genetic modification for 5LO. Forty animals, 20 WT and 20 with 5LO gene alteration (129 Alox5tm1Fun/J) (5LOKO) were divided in groups: WT, treated with 0.01 ml of sterile 0.9% saline solution (SS) intraperitoneal (IP), and ZL, treated with 250µg/Kg of ZL IP diluted in SS, both administered once a week for 7 weeks. Groups contained 5 animals each (WT Control ­ 7 and 21 days, WT ZL ,7 and 21 days, 5LOKO Control, 7 and 21 days, and 5LOKO ZL, 7 and 21 days), and the maxillae removed for microCT, histopathology, birefringence, immunohistochemistry, and histomorphometric analysis. In general, microCT revealed significant deficiency in bone microarchitecture in WT ZL group in comparison to the other groups. In the same way, histopathological and birefringence analysis revealed histological pattern compatible with ON development in WT ZL group, presenting intense inflammatory infiltrate, late new bone formation, presence of pathological fractures, and deficiency in collagenous matrix, and also in Runx-2+, TRAP+, and F4/80. 5LOKO ZL animals presented alterations compatible with a late bone repair, especially at day 7, with decreased number of Runx-2+ cells in comparison to 5LOKO Control, and by the quality of collagenous bone matrix with decreased number of red spectra fibers in this period, however, being similar at day 21. From this, it could be concluded that alveolar bone repair of 129/SV WT and 5LOKO old female mice associated with the administration of ZL occurred in different ways, leading to a picture of ON in the WT animals, and late bone repair in the 5LOKO animals, without histopathological signs that could characterize the disease. In this way, inhibition of 5LO seems to influence intramembranous alveolar bone repair in a positive way, even in the presence of osteopetrotic skeletal phenotype, suggesting other factors related to the drug that favors the development of the ON in the present animal model(AU)